Here we report for the first time that ERCC6L knockdown significantly inhibited cell proliferation in vitro and supressed tumor growth in vivo, and its high expression is significantly associated with bad outcome and progress in cancers, at least in breast and kidney cancers. This evidence concerns the gene ERCC6L and kidney cancer.